{"id":"NCT01724021","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a","officialTitle":"A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2015-01","completion":"2015-01","firstPosted":"2012-11-09","resultsPosted":"2016-08-29","lastUpdate":"2018-01-23"},"enrollment":743,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma"],"interventions":[{"type":"DRUG","name":"Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)","otherNames":[]},{"type":"DRUG","name":"Bendamustine","otherNames":["Treanda"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan","MabThera"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan","MabThera"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan","MabThera"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan","MabThera"]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"EXPERIMENTAL"}],"summary":"This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin's lymphoma. In Arm A, participants will receive MabThera/Rituxan 375 mg/m2 intravenously (IV) on Day 1 of Cycle 1 and MabThera/Rituxan 1400 mg subcutaneously (SC) on Day 1 of Cycles 2-4, followed by MabThera/Rituxan IV in Cycles 5-8. Participants in Arm B will receive MabThera/Rituxan IV in Cycles 1-4 and SC in Cycles 5-8. All participants will receive 6-8 cycles of standard chemotherapy (according to local country practice) with 8 cycles of MabThera/Rituxan. Anticipated time on study treatment is up to 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6","timeFrame":"Cycle 6 (Up to 24 weeks)","effectByArm":[{"arm":"Arm A","deltaMin":79.1,"sd":null},{"arm":"Arm B","deltaMin":80.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":246,"countries":["Argentina","Australia","Austria","Brazil","Canada","Chile","Colombia","Croatia","Denmark","Dominican Republic","Egypt","El Salvador","Germany","Guatemala","Hong Kong","Hungary","Indonesia","Italy","Malaysia","Netherlands","New Zealand","Panama","Peru","Philippines","Portugal","Romania","South Korea","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Vietnam"]},"refs":{"pmids":["28031173","27695295"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":126,"n":371},"commonTop":["Nausea","Fatigue","Anaemia","Neutrophil count decreased","Neutropenia"]}}